Shuren is retiring after 15 years as head of the FDA Center for Devices and Radiological Health.
Jeff Shuren, the longtime director of the US Food and Drug Administration’s Center for Devices and Radiological Health, plans to retire at the end of the month after 15 years in the position, he announced 23 July.
Shuren has led CDRH since 2009 and overseen several key initiatives, including an overhaul of the clinical trials program, the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
